|
Synonyms: Example No. 15 [US12351576]
Compound class:
Synthetic organic
Comment: Lavengratinib is the INN for a fibroblast growth factor receptor FGFR) inhibitor with antineoplastic potential that was included in WHO INN Proposed List 135 (July 2026). It is one of the compounds claimed in Abbisko Therapeutics' patent US12351576B2 [2]. The patent suggests that its compounds particularly inhibit the enzymatic activity of FGFR2 and/or FGFR3 kinases. Abbisko Therapeutics have a declared FGFR2/3 inhibitor in development, named ABSK061 [1], that could be a candidate for the INN.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| ABSK061 was progressed as an anti-tumour agent with potential to treat solid tumors with FGFR2/3 alterations. It may also have application in the treatment of achondroplasia. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT07297875 | A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia | Phase 1/Phase 2 Interventional | Abbisko Therapeutics Co, Ltd | ||
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | Phase 2 Interventional | Abbisko Therapeutics Co, Ltd | ||